CiPA in-silico modelling meeting

There’s an effort underway to evaluate, improve and implement mathematical models of cardiac electrophysiology for pharmaceutical cardiac safety testing and regulatory practice. In particular, to be part of a more mechanistic and accurate in-vitro assessment of pro-arrhythmic risk than the existing human clinical ThoroughQT trial. The intended replacement is called the Comprehensive In-vitro Pro-arrhythmia Assay, or CiPA for short.

This is just a short post to let everyone know that the CiPA in-silico Working Group is organising a meeting on November 9th 2017 in Toronto, dedicated to discussing the mathematical modelling aspects of CiPA. You can find more information about the meeting on this page, and register for the meeting on this page.

The plan is for the FDA modelling team to present the work they have been doing to the cardiac modelling community, to get feedback, encourage work in this area, and to network and start new collaborations. Also note there are a handful of speaker slots we are keeping free for late-breaking-abstracts which you can email me to submit short abstracts for (details here) by 30th September.

Please pass this message on to anyone you think may be interested.

Hope to see lots of you there!


This entry was posted in Action Potential Models, Drug action, Future developments, Ion Channel Models, Model Development, Safety Pharmacology and tagged , , . Bookmark the permalink.

One Response to CiPA in-silico modelling meeting

  1. Pingback: A report on the Toronto CiPA in-silico modelling workshop | Mathematical Matters of the Heart

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s